We are independent & ad-supported. We may earn a commission for purchases made through our links.
Advertiser Disclosure
Our website is an independent, advertising-supported platform. We provide our content free of charge to our readers, and to keep it that way, we rely on revenue generated through advertisements and affiliate partnerships. This means that when you click on certain links on our site and make a purchase, we may earn a commission. Learn more.
How We Make Money
We sustain our operations through affiliate commissions and advertising. If you click on an affiliate link and make a purchase, we may receive a commission from the merchant at no additional cost to you. We also display advertisements on our website, which help generate revenue to support our work and keep our content free for readers. Our editorial team operates independently of our advertising and affiliate partnerships to ensure that our content remains unbiased and focused on providing you with the best information and recommendations based on thorough research and honest evaluations. To remain transparent, we’ve provided a list of our current affiliate partners here.
Health

Our Promise to you

Founded in 2002, our company has been a trusted resource for readers seeking informative and engaging content. Our dedication to quality remains unwavering—and will never change. We follow a strict editorial policy, ensuring that our content is authored by highly qualified professionals and edited by subject matter experts. This guarantees that everything we publish is objective, accurate, and trustworthy.

Over the years, we've refined our approach to cover a wide range of topics, providing readers with reliable and practical advice to enhance their knowledge and skills. That's why millions of readers turn to us each year. Join us in celebrating the joy of learning, guided by standards you can trust.

What Factors Affect Humira® Dosage?

By Canaan Downs
Updated: May 17, 2024
Views: 5,190
References
Share

Humira® is a medication used to treat a broad spectrum of autoimmune diseases, or diseases caused by the body's own immune system mistakenly attacking its own cells. Also sold as the generic drug adalimumab, Humira® has been subjected to increasing scrutiny since its initial approval by the United States Food and Drug Administration for the treatment of rheumatoid arthritis. There are serious concerns that the use of Humira® and other tumor necrosis factor alpha blocking drugs may cause hepatosplenic T-cell lymphoma — an ordinarily rare and usually fatal form of leukemia — in children treated for autoimmune disorders. These medications have since been given a black box warning, alerting patients and prescribers that they increase the risk of developing serious bacterial, fungal, mycobacterial, viral and parasitic infection in multiple organ systems that may lead to hospitalization or death. Due to these very real risks, it is important to consider factors like the age, weight, and condition of the patient to determine the lowest possible effective Humira® dosage.

The standard Humira® dosage for polyarticular juvenile idiopathic arthritis is calculated primarily on the basis of weight. For patients between the ages of four and 17, weighing more than 66 lbs (30 kg), an Humira® dosage regimen of 40 mg by injection once every two weeks should be used. Pediatric patients that weigh between 33 lbs (15 kg) and 66 lbs (30 kg) should receive 20 mg of Humira® once per two-week period. While the medication has been used for patients weighing less than 33 lbs (15 kg), insufficient data exists to make a recommendation. The Humira® dosage is the same for patients receiving the drug as a monotherapy and with those receiving non-steroidal anti-inflammatory drugs, glucocorticoids or other analgesics as well.

In adult patients, the standard Humira® dosage for psoriatic arthritis, rheumatoid arthritis, or ankylosing spondylitis is the same as that of pediatric patients weighing over 66 lbs (30 kg): 40 mg by injection given once every two weeks. Patients receiving the medication alongside other medications to control pain and inflammation do not require adjustments to their dosage. Those not receiving methotrexate, however, may benefit from increasing the Humira® dosage to one injection per week.

Patients electing to use the medication for Crohn's disease should receive an initial breakthrough dose of 160 mg, given as either four injections of 40 mg in one day or two 40 mg injections on two consecutive days. After 14 days, two 40 mg injections should be administered. Another 14 days after this dose, the standard 40 mg maintenance regimen should be started, with subsequent 40 mg doses given every 14 days. The safety of this regimen for Crohn's disease treatment has not been evaluated for periods longer than one year.

The safety of Humira® for the treatment of plaque psoriasis has not been evaluated for periods longer than one year. As with Crohn's disease, an initial breakthrough dose is recommended. Two 40 mg injections should be administered on the first day of treatment. After 14 days, the standard adult maintenance dosage regimen of 40 mg administered once every two weeks should be used.

Share
WiseGeek is dedicated to providing accurate and trustworthy information. We carefully select reputable sources and employ a rigorous fact-checking process to maintain the highest standards. To learn more about our commitment to accuracy, read our editorial process.
Link to Sources

Editors' Picks

Discussion Comments
Share
https://www.wisegeek.net/what-factors-affect-humira-dosage.htm
Copy this link
WiseGeek, in your inbox

Our latest articles, guides, and more, delivered daily.

WiseGeek, in your inbox

Our latest articles, guides, and more, delivered daily.